Subscribe to Newsletter
Outside the Lab Biochemistry and molecular biology, Clinical care, Genetics and epigenetics, Hematology, Laboratory management, Technology and innovation, Oncology, Microbiology and immunology, Precision medicine, Screening and monitoring, Point of care testing, Omics

Pre-Empting Relapse

Acute myeloid leukemia (AML) is the most common type of blood cancer in adults. Starting suddenly and progressing rapidly, even those who achieve remission can’t breathe easy; as many as one-third of patients who receive chemotherapy and a bone marrow transplant will relapse within three to six months. Unfortunately, transplantation is the only curative treatment for AML, so patients who relapse are left with few options.

Zhaolei Zhang, Principal Investigator in the University of Toronto’s Donnelly Centre for Cellular and Biomolecular Research, believes a new DNA-based technique will improve the long-term survival of AML patients by predicting relapse after treatment. Using next generation sequencing (NGS), the test can detect mutations in the bone marrow that indicate the presence of treatment-resistant cancer cells. Although chemotherapy eliminates most of these leukemia cells, some persist after the patient has received a bone marrow transplant. The test can detect these mutations in the bone marrow three weeks after transplant, indicating that the cancer will likely return. “The early detection of actionable mutations after transplantation will increase the number of targeted therapeutic interventions available before relapse occurs, improving survival chances,” Zhang says.

“After 21 days post-transplantation, we observed that close to 60 percent of patients with these treatment-resistant mutations relapsed, whereas only around 15 percent of those without the mutations relapsed,” continues Zhang. Until now, the high cost of NGS assays made the analysis of such large amounts of generated data a challenge. However, technological advances and the development of sophisticated computational methods have made NGS assay analysis feasible. Zhang’s team hope to replicate the observations of their study in multiple hospital sites and with larger cohorts before eventually getting regulatory approval for the test’s use in clinics.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. T Kim et al., “Next-generation sequencing based post-transplant monitoring of acute myeloid leukemia”, Blood, [Epub ahead of print] (2018). PMID: 30108064.
About the Author
Luke Turner

While completing my undergraduate degree in Biology, I soon discovered that my passion and strength was for writing about science rather than working in the lab. My master’s degree in Science Communication allowed me to develop my science writing skills and I was lucky enough to come to Texere Publishing straight from University. Here I am given the opportunity to write about cutting edge research and engage with leading scientists, while also being part of a fantastic team!

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register